The Antipsychotic Drug Lurasidone Inhibits Coronaviruses by Affecting Multiple Targets

Overview

Journal Front Cell Infect Microbiol

Specialties Cell Biology
Infectious Diseases
Microbiology

Date 2024 Dec 10

PMID 39654978

Authors

Sara Baroni

Tea Carletti

Manuela Donalisio

Irene Arduino

Irene Cazzaniga

Toni Giorgino

Francesca Esposito

Alessia Porta

Luisa Diomede

Ada De Luigi

Marco Gobbi

David Lembo

Alessandro Marcello

Enzo Tramontano

Mario Milani

Eloise Mastrangelo

Affiliations

Soon will be listed here.

Abstract

Coronaviruses (CoVs) share key genomic elements critical for viral replication, suggesting the feasibility of developing therapeutics with efficacy across different viruses. In a previous work, we demonstrated the antiviral activity of the antipsychotic drug lurasidone against both SARS-CoV-2 and HCoV-OC43. In this study, our investigations on the mechanism of action of lurasidone suggested that the drug exhibits antiviral activity by targeting the papain-like protease (PL-Pro) of both viruses, and the Spike protein of SARS-CoV-2, thereby hampering both the entry and the viral replication. assays demonstrate that lurasidone significantly reduces viral load in infected cells, showing that the drug is a promising candidate for further development as a dual-action antiviral, offering a potential new strategy in the fight against COVID-19 and other coronavirus-related diseases.

References

Mishchenko E, V A Ivanisenko V . Replication-transcription complex of coronaviruses: functions of individual viral non-structural subunits, properties and architecture of their complexes. Vavilovskii Zhurnal Genet Selektsii. 2022; 26(2):121-127. PMC: 8983304. DOI: 10.18699/VJGB-22-15. View

Osipiuk J, Azizi S, Dvorkin S, Endres M, Jedrzejczak R, Jones K . Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors. Nat Commun. 2021; 12(1):743. PMC: 7854729. DOI: 10.1038/s41467-021-21060-3. View

Nizi M, Persoons L, Corona A, Felicetti T, Cernicchi G, Massari S . Discovery of 2-Phenylquinolines with Broad-Spectrum Anti-coronavirus Activity. ACS Med Chem Lett. 2022; 13(5):855-864. PMC: 9088073. DOI: 10.1021/acsmedchemlett.2c00123. View

Beeg M, Baroni S, Piotti A, Porta A, De Luigi A, Cagnotto A . A Comprehensive Technology Platform for the Rapid Discovery of Peptide Inhibitors against SARS-CoV-2 Pseudovirus Infection. Int J Mol Sci. 2023; 24(15). PMC: 10418426. DOI: 10.3390/ijms241512146. View

Agostini M, Andres E, Sims A, Graham R, Sheahan T, Lu X . Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio. 2018; 9(2). PMC: 5844999. DOI: 10.1128/mBio.00221-18. View

Biolatti M, Blangetti M, Baggieri M, Marchi A, Gioacchini S, Bajetto G . Strigolactones as Broad-Spectrum Antivirals against β-Coronaviruses through Targeting the Main Protease M. ACS Infect Dis. 2023; 9(7):1310-1318. DOI: 10.1021/acsinfecdis.3c00219. View

Laskowski R, Swindells M . LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model. 2011; 51(10):2778-86. DOI: 10.1021/ci200227u. View

Fumagalli V, Di Lucia P, Rava M, Marotta D, Bono E, Grassi S . Nirmatrelvir treatment of SARS-CoV-2-infected mice blunts antiviral adaptive immune responses. EMBO Mol Med. 2023; 15(5):e17580. PMC: 10165354. DOI: 10.15252/emmm.202317580. View

Bawa R, Scarff J . Lurasidone: a new treatment option for bipolar depression-a review. Innov Clin Neurosci. 2015; 12(1-2):21-3. PMC: 4382136. View

10.

Fu Z, Huang B, Tang J, Liu S, Liu M, Ye Y . The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery. Nat Commun. 2021; 12(1):488. PMC: 7817691. DOI: 10.1038/s41467-020-20718-8. View

11.

Licastro D, Rajasekharan S, Dal Monego S, Segat L, DAgaro P, Marcello A . Isolation and Full-Length Genome Characterization of SARS-CoV-2 from COVID-19 Cases in Northern Italy. J Virol. 2020; 94(11). PMC: 7269454. DOI: 10.1128/JVI.00543-20. View

12.

Teli D, Balar P, Patel K, Sharma A, Chavda V, Vora L . Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants. Metabolites. 2023; 13(2). PMC: 9962121. DOI: 10.3390/metabo13020309. View

13.

Schirtzinger E, Kim Y, Davis A . Improving human coronavirus OC43 (HCoV-OC43) research comparability in studies using HCoV-OC43 as a surrogate for SARS-CoV-2. J Virol Methods. 2021; 299:114317. PMC: 8500843. DOI: 10.1016/j.jviromet.2021.114317. View

14.

Dejmek M, Konkolova E, Eyer L, Strakova P, Svoboda P, Sala M . Non-Nucleotide RNA-Dependent RNA Polymerase Inhibitor That Blocks SARS-CoV-2 Replication. Viruses. 2021; 13(8). PMC: 8402726. DOI: 10.3390/v13081585. View

15.

Milani M, Donalisio M, Milan Bonotto R, Schneider E, Arduino I, Boni F . Combined in silico and in vitro approaches identified the antipsychotic drug lurasidone and the antiviral drug elbasvir as SARS-CoV2 and HCoV-OC43 inhibitors. Antiviral Res. 2021; 189:105055. PMC: 7944860. DOI: 10.1016/j.antiviral.2021.105055. View

16.

McNutt A, Francoeur P, Aggarwal R, Masuda T, Meli R, Ragoza M . GNINA 1.0: molecular docking with deep learning. J Cheminform. 2021; 13(1):43. PMC: 8191141. DOI: 10.1186/s13321-021-00522-2. View

17.

Savoie C, Lippe R . Optimizing human coronavirus OC43 growth and titration. PeerJ. 2022; 10:e13721. PMC: 9272819. DOI: 10.7717/peerj.13721. View

18.

Mirdita M, Schutze K, Moriwaki Y, Heo L, Ovchinnikov S, Steinegger M . ColabFold: making protein folding accessible to all. Nat Methods. 2022; 19(6):679-682. PMC: 9184281. DOI: 10.1038/s41592-022-01488-1. View

19.

Owczarek K, Szczepanski A, Milewska A, Baster Z, Rajfur Z, Sarna M . Early events during human coronavirus OC43 entry to the cell. Sci Rep. 2018; 8(1):7124. PMC: 5940804. DOI: 10.1038/s41598-018-25640-0. View

20.

Min J, Kim D, Jin Y, Kwon S . Kurarinone Inhibits HCoV-OC43 Infection by Impairing the Virus-Induced Autophagic Flux in MRC-5 Human Lung Cells. J Clin Med. 2020; 9(7). PMC: 7408680. DOI: 10.3390/jcm9072230. View